Howard Cheng, MD | Authors

A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor

April 01, 2002

Among the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.